Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 28.60 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 19.16 | Oscillator | Buy |
| Williams %R (14) | -92.31 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.16 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 55.76 (+DI 4.4 / -DI 29.1) | Trend | Strong Sell |
Current price $1.81
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 2, 26 | HC Wainwright & Co. |
| EMA 20 | 1.99 | MA | Strong Sell |
| SMA 20 | 2.00 | MA | Strong Sell |
| EMA 50 | 2.33 | MA | Strong Sell |
| SMA 50 | 2.44 | MA | Strong Sell |
| SMA 200 | 3.27 | MA | Strong Sell |
| maintain |
| Buy |
| Buy |
| May 13, 26 | D. Boral Capital | upgrade | Hold | Buy |
| May 12, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 24, 25 | D. Boral Capital | downgrade | Buy | Hold |
| Dec 17, 25 | D. Boral Capital | maintain | Buy | Buy |
| Nov 18, 25 | D. Boral Capital | maintain | Buy | Buy |
| Sep 16, 25 | D. Boral Capital | maintain | Buy | Buy |
| Sep 2, 25 | D. Boral Capital | maintain | Buy | Buy |
| Jul 29, 25 | D. Boral Capital | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 4, 26 | Farbstein Motti | officer: CEO, CFO and COO | A-Award | 24,000 @ $2.04 | $49.03K |
| Jun 4, 26 |
| Fishman Pnina |
| director, officer: Chief Scientific Officer |
| A-Award |
| 24,000 @ $2.04 |
| $49.03K |
| Apr 25, 26 | Tamir Ilan | director | 16,000 @ $2.25 | $36.00K |
| Mar 18, 26 | Regev Guy | director | 0 | — |
| Feb 8, 17 | Regev Guy | director | 16 @ $2,826.14 | $45.22K |
| Jun 15, 20 | Regev Guy | director | 200 @ $241.47 | $48.29K |
| Aug 1, 23 | Regev Guy | director | 2,166 @ $25.21 | $54.60K |
| Aug 7, 24 | Regev Guy | director | 2,166 @ $26.56 | $57.53K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CANF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.3x | -3484.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.9x | EPS est. -2.04 | Elevated |
| Price / Book | 0.7x | 5272.2x | Discount |
| Price / Sales | 10.1x | 44502.8x | Discount |
| EV / EBITDA | -0.1x | -3480.3x | Discount |
| Return on equity | -182.9% | — | Weak |
| Gross margin | 100.0% | 98.8% | In line |
| Debt / Equity | 0.01 | 0.01 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -34.05 | Distress |
Discounted cash flow model
Stock news · updated daily
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer.
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson.
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the submission of a Phase 2 clinical study protocol to Bambino Gesù Children's Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome, a rare inherited genetic disorder with no approved disease-modifying therapies.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 8, 2026 | -0.33 | -1.24 | Miss -275.8% | $202.0K |
| Mar 26, 2026 | -27.00 | -5.97 | Beat 77.9% | $203.0K |
| Aug 28, 2025 | -4.15 | -0.00 | Beat 100.0% | $202.0K |
| Apr 14, 2025 | -0.10 | -0.10 | Beat 0.0% | $101.0K |
| Mar 27, 2025 | -0.24 | -0.00 | Beat 99.3% | $179.0K |
| Jan 2, 2025 | -0.27 | -0.27 | Beat 0.0% | $300.0K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| EFFECT | Oct 9, 2026 | 2026-10-13 00:15:12 | View |
| EFFECT | Oct 9, 2026 | 2026-10-13 00:15:09 | View |
| 424B3 | Oct 9, 2026 | 2026-10-09 17:15:10 | View |
| F-3 | Sep 25, 2026 | 2026-09-28 13:53:44 | View |
| F-3/A | Sep 25, 2026 | 2026-09-25 16:30:50 | View |
| EFFECT | Sep 11, 2026 | 2026-09-14 00:15:05 | View |
| EFFECT | Sep 11, 2026 | 2026-09-14 00:15:03 | View |
| D | Sep 10, 2026 | 2026-09-10 17:00:04 | View |
| 6-K | Sep 9, 2026 | 2026-09-09 07:02:10 | View |
| POS AM | Sep 8, 2026 | 2026-09-08 16:33:31 | View |
Proxy statement (DEF 14A) disclosures